Cationic Copolymer Polyplexes for CRISPR Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies face challenges with the high costs, logistical bottlenecks, and regulatory hurdles associated with viral vectors for widespread clinical deployment of CRISPR-based therapeutics, particularly due to immunogenicity and size limitations, necessitating the development of synthetic substitutes for viral carriers.
Innovation Solution
The use of novel polymeric gene delivery vehicles, specifically copolymers formed from cationic and neutral monomers, to create interpolyelectrolyte complexes (polyplexes) that efficiently deliver CRISPR payloads, such as mRNA and ribonucleoproteins, by optimizing physicochemical properties like composition, molecular weight, and ζ-potential for enhanced gene editing efficiency and reduced cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used to deliver CRISPR payloads, then delivery efficiency is improved, but manufacturing cost and logistical complexity increase
Solution Approach 1:
The patent replaces expensive, complex viral vectors with inexpensive synthetic polymeric carriers that can be manufactured at scale without the regulatory and logistical burdens of viral production. The polyplexes are designed for single-use delivery, eliminating the need for costly viral vector manufacturing while maintaining effective gene delivery.
Solution Approach 2:
The patent creates synthetic polymeric copies that mimic the delivery function of viral vectors without requiring actual viral particles. These polymer-based polyplexes replicate the essential delivery mechanism while avoiding the manufacturing complexities and high costs associated with producing clinical-grade viruses.
2Reliability
If viral vectors are used to deliver CRISPR payloads, then delivery efficiency is improved, but regulatory challenges and deployment time increase
Solution Approach 1:
The patent employs disposable synthetic polymeric carriers that eliminate the lengthy regulatory approval process required for viral vectors. These polymers can be rapidly manufactured and deployed without the extensive safety testing and regulatory oversight needed for viral-based therapies, dramatically reducing deployment time.
Solution Approach 2:
The patent extracts the essential delivery function from viral vectors, separating it from the problematic viral components that cause regulatory delays. By using only the delivery mechanism without the viral genome and associated safety concerns, the patent enables rapid deployment while maintaining delivery efficiency.
3Quantity of substance
If cationic polymers are used to deliver biomacromolecules, then payload encapsulation capacity increases, but cellular toxicity increases
Solution Approach 1:
The patent applies local quality by incorporating PEGylated segments at specific locations on the polymer chain to mask the cationic regions that cause toxicity. This creates a gradient of properties where the core maintains high encapsulation capacity while the surface provides low toxicity, resolving the contradiction between payload capacity and cellular safety.
Solution Approach 2:
The patent uses composite polymeric structures combining cationic segments for payload binding with PEGylated segments for biocompatibility. This composite approach allows the material to simultaneously achieve high encapsulation capacity through cationic interactions and reduced toxicity through the hydrophilic PEG corona.
4Ease of manufacture
If polymeric delivery systems are used instead of viral vectors, then manufacturing cost decreases, but delivery efficiency decreases
Solution Approach 1:
The patent optimizes multiple parameters of the polymeric carriers including molecular weight, charge density, PEGylation degree, and hydrodynamic radius to maximize delivery efficiency. By systematically tuning these parameters, the patent achieves viral-vector-level delivery efficiency while maintaining the manufacturing advantages of synthetic polymers.
Solution Approach 2:
The patent replaces the biological recognition mechanisms of viral vectors with engineered polymeric interactions that can be precisely controlled and optimized. This substitution allows for rational design of polyplexes with tailored delivery properties, achieving high efficiency through controlled polymer-nucleic acid interactions rather than complex viral entry mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polymeric vehicles achieve high gene editing efficiencies, surpassing commercial transfection reagents in some cases, while minimizing immune activation and cellular toxicity, thereby facilitating safe, scalable, and affordable CRISPR-based therapies.
Implementation Method 1
In aqueous physiological solutions, cationic polymers can spontaneously bind with negatively charged pDNA and form interpolyelectrolyte complexes
Data Source
AI summary
A compound includes a polymer associated with a biological agent. The polymer has a first (meth)acryl monomeric unit with a cationic functional group R1 and a second (meth)acryl monomeric unit with a neutral hydrophilic functional group R2. The cationic functional group R1 is chosen from amino groups and alkylamino groups, and the neutral functional group R2 is chosen from polyethylene glycol (PEG), hydroxyl (OH), phosphorylcholine (PC), and mixtures and combinations thereof.